Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Dhakal B et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4600. [Epub ahead of print].

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma.
Gertz MA et al. Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012.

Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U et al. Hematol Oncol. 2018 Jan 24. doi: 10.1002/hon.2490. [Epub ahead of print].

Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.
Muta T et al. Acta Haematol. 2018 Jan 17;139(1):35-44. doi: 10.1159/000484652. [Epub ahead of print].

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Siegel DS et al. J Clin Oncol. 2018 Jan 17:JCO2017765032. doi: 10.1200/JCO.2017.76.5032. [Epub ahead of print].

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Fouquet G et al. Ann Hematol. 2018 Jan 12. doi: 10.1007/s00277-018-3236-6. [Epub ahead of print].

Carfilzomib for relapsed or refractory multiple myeloma.
Tanimoto T et al. Lancet Oncol. 2018 Jan;19(1):e1. doi: 10.1016/S1470-2045(17)30859-8.

Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma.
Sidaway P. Nat Rev Clin Oncol. 2018 Jan 16. doi: 10.1038/nrclinonc.2018.1. [Epub ahead of print].
Daratumumab for untreated multiple myeloma.
Stirrups R. Lancet Oncol. 2017 Dec 21. pii: S1470-2045(17)30951-8. doi: 10.1016/S1470-2045(17)30951-8. [Epub ahead of print].